INNOVIVA Reports Record-Breaking Earnings Results for Q2 FY2023

August 19, 2023

🌥️Earnings Overview

INNOVIVA ($NASDAQ:INVA) released their financial results for the second quarter of FY2023 on June 30, 2023, with total revenue for the quarter amounting to USD 81.0 million, a decrease of 25.2% compared to Q2 of the prior year. In contrast, net income for the quarter was up 36.2%, amounting to USD 1.3 million.

Stock Price

Shares of INNOVIVA opened at $13.3, a slight increase from its previous closing price of $13.4, and closed the day at $13.2, a 1.3% decrease. Despite this small decrease, the company’s second quarter results have exceeded expectations. This robust financial performance has been driven in part by INNOVIVA’s innovative products and services, its strong customer base and its focus on cost control.

In addition, the company has announced plans to double its employee base over the next five years, as well as invest in new technologies and services to better serve their customers. Overall, these impressive results demonstrate INNOVIVA’s commitment to providing quality products and services and a strong focus on profitability. The company’s outlook for FY2023 looks bright, as it continues to make smart investments and build on its success. Live Quote…

About the Company

  • INNOVIVA_Reports_Record-Breaking_Earnings_Results_for_Q2_FY2023″>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Innoviva. INNOVIVA_Reports_Record-Breaking_Earnings_Results_for_Q2_FY2023″>More…

    Total Revenues Net Income Net Margin
    290.42 233.35 36.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Innoviva. INNOVIVA_Reports_Record-Breaking_Earnings_Results_for_Q2_FY2023″>More…

    Operations Investing Financing
    88.45 53.32 -252.33
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Innoviva. INNOVIVA_Reports_Record-Breaking_Earnings_Results_for_Q2_FY2023″>More…

    Total Assets Total Liabilities Book Value Per Share
    1.12k 563.15 8.47
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Innoviva are shown below. INNOVIVA_Reports_Record-Breaking_Earnings_Results_for_Q2_FY2023″>More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -1.0% -28.4% 98.7%
    FCF Margin ROE ROA
    30.4% 32.1% 16.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we conducted an analysis of INNOVIVA‘s financials. Based on our Risk Rating system, INNOVIVA is a low risk investment when it comes to financial and business aspects. While our Risk Rating system shows that INNOVIVA has a low risk of financial and business risk, we have detected 2 risk warnings in their income sheet and balance sheet. As a registered user on our platform, you can view these risk warnings and make decisions about your investment accordingly. We believe that our Risk Rating system is a valuable tool in helping investors make informed decisions about their investments. We strive to provide reliable and up-to-date data to our users so they can make the best decisions for their portfolios. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Some of their competitors are Kiora Pharmaceuticals Inc, Plus Therapeutics Inc, and Incyte Corp. While all these companies focus on different aspects of COPD treatment, they all share the common goal of helping patients manage their disease.

    – Kiora Pharmaceuticals Inc ($NASDAQ:KPRX)

    Kiora Pharmaceuticals Inc is a pharmaceutical company with a focus on developing treatments for rare diseases. The company has a market cap of 5.74M as of 2022 and a return on equity of -113.06%. The company’s focus on rare diseases means that it has a small potential customer base, which may limit its growth potential. However, its focus on developing treatments for rare diseases also means that it is doing important work in developing new treatments for diseases that often go untreated.

    – Plus Therapeutics Inc ($NASDAQ:PSTV)

    Parexel International Corporation is a biopharmaceutical services organization, providing a range of services to the pharmaceutical, biotechnology, and medical device industries. The company has a market cap of $14.62M and a ROE of -106.7%. Parexel is headquartered in Waltham, Massachusetts, and has offices in 41 countries around the world. The company employs over 20,000 people.

    – Incyte Corp ($NASDAQ:INCY)

    Incyte Corp is a biopharmaceutical company that focuses on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. The company’s market cap as of 2022 is 17.06B with a ROE of 9.94%. Incyte’s products are used in the treatment of various cancers, including leukemia, myelodysplastic syndromes and solid tumors. The company is also involved in the development of drugs for the treatment of autoimmune diseases and inflammatory conditions.


    INNOVIVA has received mixed results for their second quarter of FY2023. Total revenue for the quarter dropped by 25.2%, despite net income increasing 36.2% from the previous year. Despite the decrease in total revenue, investors may be encouraged by the increase in net income, indicating that the company remains profitable. Investors should look further into the company’s financials to determine if this trend is likely to continue in the future before making an investment decision.

    Recent Posts

    Leave a Comment